点击下方 卡片 ，关注" 自动驾驶之心 "公众号 戳我-> 领取 自动驾驶近15个 方向 学习 路线 MCAM：面向自车层面驾驶视频理解的多模态因果分析模型 重庆大学&国防科技大ICCV25中稿的工作，本文提出 MCAM 模型，通过 DSDAG 因果图建模自车状态动 态演化，在BDD-X数据集上将驾驶行为描述任务BLEU-4提升至 35.7%，推理任务BLEU-4提升至 9.1%，显 著优于DriveGPT4等基线模型。 主要贡献： 算法框架： 实验结果： 论文标题：MCAM: Multimodal Causal Analysis Model for Ego-Vehicle-Level Driving Video Understanding 论文链接：https://arxiv.org/abs/2507.06072 代码：https://github.com/SixCorePeach/MCAM 1. 提出驾驶状态有向无环图（DSDAG），用于建模动态驾驶交互和状态转换，为因果分析模块（CAM） 提供结构化理论基础。 2. 提出多模态因果分析模型（MCAM），这是首个针对 ego-vehicle 级驾驶视频理解 ...

Core Viewpoint - Jasper Therapeutics, Inc. is under investigation for potential securities fraud and unlawful business practices following a significant drop in stock price due to issues related to a drug product lot in a clinical study [1][2]. Group 1: Company Overview - Jasper Therapeutics, Inc. is publicly traded on NASDAQ under the ticker symbol JSPR [1]. - The company recently reported updated data from its BEACON Phase 1b/2a study of briquilimab, which is intended for adult participants with chronic spontaneous urticaria (CSU) [2]. Group 2: Recent Developments - On July 7, 2025, Jasper announced that results from certain dose cohorts of its clinical study were confounded by issues with a specific drug product lot, affecting 10 out of 13 patients in those cohorts [2]. - Following this announcement, Jasper's stock price plummeted by $3.73 per share, representing a 55.1% decrease, closing at $3.04 per share on the same day [2]. Group 3: Legal Context - Pomerantz LLP is investigating claims on behalf of Jasper investors, focusing on potential securities fraud and misconduct by the company and its officers or directors [1]. - The Pomerantz Firm has a long history in corporate and securities class litigation, having recovered significant damages for victims of securities fraud [3].

| 15:47 @ 9 | | | 112 2 111 2 30 | | | --- | --- | --- | --- | --- | | Q | 園 | | | (7 | | 美国 ▲ | 本档期 暑期档/06.01-08.31▼ ●含服务费 | | | | | | 〈返回今日 | | | | | 六 | 30.2 亿 | | | | | 档 | 含预售实时 北京时间15:47:18 ① | | | 档 | | 总出票7665.5万张 ① 总场次1765.4万场 | | | 平均票价39.4元 | | | 票房排名 | | | | 更多指标 ▶ | | 影片 | 档期票房 票房占比 | | 排片占比 | 上座率 | | | (万) | | | | | 侏罗纪世界: 重生 2025-07-02上映 | 41025.21 | 13.5% | 7.7% | 4.7% | | 酱园弄·悬案 2025-06-21上映 | 37235.55 | 12.3% | 10.1% | 4.0% | | 碟中谍8: 最终清 賞 | 35228.38 | 11.6% | 9.5% | 3.4% | | 2025-05-30上映 ...

IMAX on pace for a record year at the box office and analysts expect next year is going to be even better. The move has been driven by high-profile releases like F1 sinners and the latest Mission Impossible. And this month we get Superman and the Fantastic 4.IMAX shares are up over 50% in the past year. Joining us now is Richard Gelfund, IMAX CEO. Rich, it's great to have you on.Uh, and let's start right there. Box office is booming. What's driving it.Um, let's start with the simplest thing, Morgan. really ...

JENA, Germany, July 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it has received a written notice (the “Notice”), dated July 11, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company’s common shares had closed below the minimum $1.00 pe ...

AMC Entertainment AMC stock surged on Friday after Wedbush analyst Alicia Reese upgraded it from Neutral to Outperform and raised its price forecast from $3 to $4.Reese noted that AMC will benefit from a steadier film release schedule in the coming quarters, which should support consistent box office performance.According to the analyst, the company is well-positioned to gain market share in 2025 and 2026, thanks to its ownership of the highest number of premium screens in North America and expansion effort ...

Group 1 - MSCI Inc. provides index services, data analytics, risk management, and sustainability and climate solutions to the financial market [1] - The company has diversified its business lines beyond its ETF offerings in recent years [1]

Community CornerMan Killed On I-55 Was Helping Stalled Car: GoFundMeThe 30-year-old was helping repair a vehicle on the side of the interstate when a car hit him, according to the GoFundMe."Bosimbek [Khazratqulov] was only 30 years old — full of dreams and hopes," the GoFundMe organizer said of the Aurora man who was killed July 5 on Interstate 55. (Shutterstock)PLAINFIELD, IL — Bosimbek Khazratqulov was helping someone repair a car July 5 on the side of Interstate 55 near Plainfield when he was struck and ...

Core Insights - Teva Pharmaceutical Industries Limited's shares have increased by 21.6% over the past three months due to successful launches of biosimilars and high-value generics, strong sales growth of newer branded drugs, and cost-cutting measures [1] Branded Drug Growth - Teva is experiencing market share growth for its newest branded drugs, Austedo and Ajovy, with expectations for continued sales growth from patient expansion and international launches [3] - The company anticipates annual revenues exceeding $2.5 billion from Austedo by 2027, bolstered by the launch of Austedo XR [4] - Uzedy, launched in May 2023, is projected to generate approximately $160 million in sales by 2025 [5] - Teva's branded pipeline includes olanzapine and duvakitug, with plans for phase III trials and new drug applications in the coming years [6][7] Generics and Biosimilars Pipeline - Teva has launched several biosimilars and complex generics, including products from major pharmaceutical companies [8] - The company has a strong pipeline of biosimilars, with plans to launch seven in the U.S. and four in Europe between 2025 and 2027 [10] - Teva's U.S. generics and biosimilars business grew by 15% in 2024, driven by new product launches [11] Financial Performance and Valuation - Teva's stock has underperformed the industry, losing 25% year-to-date compared to a 9.5% decline in the industry [13][14] - The stock is trading at a price/earnings ratio of 6.30, lower than the industry average of 10.17, but above its 5-year mean of 4.11 [15] - The Zacks Consensus Estimate for earnings has seen a slight decline for 2025 but an increase for 2026 [19] Long-term Growth Prospects - Teva's newer drugs and stable generics business are contributing to a revival in top-line growth [21] - The company is optimizing operations for efficiency, aiming for an adjusted operating margin of 30% by 2027 [22] - Recent credit outlook upgrades from Fitch, Moody's, and S&P reflect improved growth prospects for Teva [23]

Company Performance - IMAX's partnership with Apple for "F1: The Movie" contributed to nearly $300 million in global box office revenue within the first 10 days of release, with over 20% of that revenue coming from IMAX screenings [1][2] - In the U.S. and Canada, IMAX theaters accounted for 25% of all domestic ticket sales for "F1: The Movie," despite IMAX screens representing less than 1% of total movie screens worldwide [2] - CEO Rich Gelfond forecasts a record $1.2 billion in global box office revenue for IMAX in 2025, which would be a 33% increase from 2024 [3] Market Trends - The film industry is witnessing a shift towards premium experiences, with IMAX gaining market share and poised for exponential growth [3] - Post-pandemic, premium brands in various sectors, including concerts and sporting events, have seen increased demand, indicating a consumer preference for distinctive experiences when going out [4] Stock Performance - IMAX stock has seen a significant rally, with shares increasing approximately 60% over the past 12 months [4]